Limits...
Effect of Aloe barbadensis Mill. formulation on Letrozole induced polycystic ovarian syndrome rat model.

Maharjan R, Nagar PS, Nampoothiri L - J Ayurveda Integr Med (2010)

Bottom Line: Co-treatment of the inductive agent (letrozole) with the Aloe vera gel prevented the development of the PCO phenotype.Aloe vera gel formulation exerts a protective effect in against the PCOS phenotype by restoring the ovarian steroid status, and altering key steroidogenic activity.This can be attributed to phyto-components present in the extract.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, M.S. University of Baroda, Vadodara, Gujarat, India.

ABSTRACT
This is a preliminary study that explores the efficacy of Aloe vera gel formulation as a possible therapeutic agent in the prevention and management of polycystic ovary syndrome (PCOS). PCOS is recognized as the most common endocrinopathy of women. Increased androgen synthesis, disrupted folliculogenesis, and insulin resistance lie at the patho-physiological core of PCOS. Current therapy for such a syndrome is use of insulin sensitizers. Large randomized clinical trials of metformin as the insulin-sensitizing drug, however, suggested that it produces many side effects after prolonged usage. For this reason, an alternate therapy would be to use herbs with hypoglycemic potential. Aloe barbadensis Mill. (Liliaceae) popularly known as Aloe vera is a well-known plant with such properties. The present study evaluated the efficacy of Aloe vera gel formulation in a PCOS rat model. Five month old Charles Foster female rats were orally fed with letrozole, a non-steroidal aromatase inhibitor, to induce PCOS. The rats were then treated orally with the Aloe vera gel formulation (1 ml dose daily for 45 days). This restored their estrus cyclicity, glucose sensitivity, and steroidogenic activity. Co-treatment of the inductive agent (letrozole) with the Aloe vera gel prevented the development of the PCO phenotype. Aloe vera gel formulation exerts a protective effect in against the PCOS phenotype by restoring the ovarian steroid status, and altering key steroidogenic activity. This can be attributed to phyto-components present in the extract.

No MeSH data available.


Related in: MedlinePlus

“In vitro” effect of aloe vera gel formulation on ovarian steroidogenic enzyme activity on letrozole induced rats model, n=4-6. The values are represented as mean ± SEM, *P<0.001, ***P<0.003 as compared to Control Group, aP <0.05, @P<0.02, bP<0.004, #P<0.003, $P<0.002 as compared to PCOS Group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3117319&req=5

Figure 0004: “In vitro” effect of aloe vera gel formulation on ovarian steroidogenic enzyme activity on letrozole induced rats model, n=4-6. The values are represented as mean ± SEM, *P<0.001, ***P<0.003 as compared to Control Group, aP <0.05, @P<0.02, bP<0.004, #P<0.003, $P<0.002 as compared to PCOS Group.

Mentions: Direct effect of AVG was evaluated by in vitro incubation with PCOS rat ovarian protein. Ovarian steroidogenic enzymes 3β HSD and 17β HSD activity in “in vitro” incubations yielded activity similar to control and metformin groups, suggesting that AVG acts directly on the ovarian enzymes [Figure 4].


Effect of Aloe barbadensis Mill. formulation on Letrozole induced polycystic ovarian syndrome rat model.

Maharjan R, Nagar PS, Nampoothiri L - J Ayurveda Integr Med (2010)

“In vitro” effect of aloe vera gel formulation on ovarian steroidogenic enzyme activity on letrozole induced rats model, n=4-6. The values are represented as mean ± SEM, *P<0.001, ***P<0.003 as compared to Control Group, aP <0.05, @P<0.02, bP<0.004, #P<0.003, $P<0.002 as compared to PCOS Group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3117319&req=5

Figure 0004: “In vitro” effect of aloe vera gel formulation on ovarian steroidogenic enzyme activity on letrozole induced rats model, n=4-6. The values are represented as mean ± SEM, *P<0.001, ***P<0.003 as compared to Control Group, aP <0.05, @P<0.02, bP<0.004, #P<0.003, $P<0.002 as compared to PCOS Group.
Mentions: Direct effect of AVG was evaluated by in vitro incubation with PCOS rat ovarian protein. Ovarian steroidogenic enzymes 3β HSD and 17β HSD activity in “in vitro” incubations yielded activity similar to control and metformin groups, suggesting that AVG acts directly on the ovarian enzymes [Figure 4].

Bottom Line: Co-treatment of the inductive agent (letrozole) with the Aloe vera gel prevented the development of the PCO phenotype.Aloe vera gel formulation exerts a protective effect in against the PCOS phenotype by restoring the ovarian steroid status, and altering key steroidogenic activity.This can be attributed to phyto-components present in the extract.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, M.S. University of Baroda, Vadodara, Gujarat, India.

ABSTRACT
This is a preliminary study that explores the efficacy of Aloe vera gel formulation as a possible therapeutic agent in the prevention and management of polycystic ovary syndrome (PCOS). PCOS is recognized as the most common endocrinopathy of women. Increased androgen synthesis, disrupted folliculogenesis, and insulin resistance lie at the patho-physiological core of PCOS. Current therapy for such a syndrome is use of insulin sensitizers. Large randomized clinical trials of metformin as the insulin-sensitizing drug, however, suggested that it produces many side effects after prolonged usage. For this reason, an alternate therapy would be to use herbs with hypoglycemic potential. Aloe barbadensis Mill. (Liliaceae) popularly known as Aloe vera is a well-known plant with such properties. The present study evaluated the efficacy of Aloe vera gel formulation in a PCOS rat model. Five month old Charles Foster female rats were orally fed with letrozole, a non-steroidal aromatase inhibitor, to induce PCOS. The rats were then treated orally with the Aloe vera gel formulation (1 ml dose daily for 45 days). This restored their estrus cyclicity, glucose sensitivity, and steroidogenic activity. Co-treatment of the inductive agent (letrozole) with the Aloe vera gel prevented the development of the PCO phenotype. Aloe vera gel formulation exerts a protective effect in against the PCOS phenotype by restoring the ovarian steroid status, and altering key steroidogenic activity. This can be attributed to phyto-components present in the extract.

No MeSH data available.


Related in: MedlinePlus